UBS Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

UBS Group’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,200,320	Closed	-$39.3M	–	10727
2026 Q1	$39.3M	Hold	11,200,320	–	–	0.01%	1881
2025 Q4	$37.7M	Hold	11,200,320	–	–	0.01%	1938
2025 Q3	$14.7M	Hold	11,200,320	–	–	﹤0.01%	2901
2025 Q2	$8.03M	Hold	11,200,320	–	–	﹤0.01%	3334
2025 Q1	$16.5M	Hold	11,200,320	–	–	﹤0.01%	2545
2024 Q4	$49.6M	Hold	11,200,320	–	–	0.01%	1472
2024 Q3	$46.1M	Hold	11,200,320	–	–	0.01%	1195
2024 Q2	$73M	Sell	11,200,320 -11,200,320	-50%	-$79.2M	0.02%	808
2024 Q1	$195M	Buy	+22,400,640	New	+$272M	0.05%	377
2022 Q1	–	Sell	-30,600	Closed	-$357K	–	10557
2021 Q4	$357K	Hold	30,600	–	–	﹤0.01%	5247
2021 Q3	$400K	Hold	30,600	–	–	﹤0.01%	4870
2021 Q2	$394K	Hold	30,600	–	–	﹤0.01%	4899
2021 Q1	$342K	Hold	30,600	–	–	﹤0.01%	5131
2020 Q4	$349K	Buy	+30,600	New	+$335K	﹤0.01%	4867
2015 Q2	–	Sell	-107,460	Closed	-$1.44M	–	8666
2015 Q1	$1.44M	Buy	+107,460	New	+$1.41M	﹤0.01%	3231

Other funds holding IRWD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's IRWD Position: Q2 2026 in Review

UBS Group reduced its Ironwood Pharmaceuticals (IRWD) stake by 58% in Q2 2026, selling an estimated $2.1M and leaving 389,529 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5292.

UBS Group first reported a position in IRWD in Q4 2014 and has held it in 47 quarters since. The position peaked at $26.4M in Q1 2024. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

UBS Group held 389,529 shares of Ironwood Pharmaceuticals worth $1.64M as of Q2 2026.
UBS Group sold 543,696 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
Ironwood Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5292 holding.
UBS Group first reported a position in Ironwood Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
UBS Group's Ironwood Pharmaceuticals position peaked at $26.4M in Q1 2024.
212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.